Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07732218) titled 'Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial' on July 23.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Rehman Medical Institute - RMI

Condition: Type 2 Diabetes

Intervention: Drug: Semaglutide (Ozempic(R))

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: July 4, 2022

Target Sample Size: 95

Countries of Recruitment: Pakistan

To know more, visit https://clinicaltrials.gov/study/NCT07732218

Di...